Farmak has supplemented the Moleskin® dermatological line. Domestic pharmaceutical manufacturer specialists have developed and brought to market a combination drug product Moleskin C in the form of an ointment used to treat chronic skin diseases.
Moleskin C is a combination drug product containing an anti-inflammatory, anti-pruritic and anti-allergic component mometasone furoate and exfoliating component salicylic acid.
Moleskin C is used to treat chronic dermatological diseases such as psoriasis, eczema, dermatitis etc., which are accompanied by coarse skin and impaired keratinization.
Olena Alexeeva, Marketing Consultant, Farmak Marketing Department for Prescription Drug Products: “Mometasone furoate which is a component of Moleskin C is the safest topical hormonal drug and does not cause local or systemic side effects even during prolonged use. Mometasone quickly relieves major symptoms of dermatitis (itching, inflammation and redness). It is the only topical hormonal agent, the evidence base of which includes the research conducted in Germany among 22,831 patients involving 5,500 physicians. The study recorded no side effects with maximum anti-pruritic and anti-inflammatory efficacy.
Salicylic acid, a component of the new formula, shows antiseptic and anti-inflammatory action, softens thickened exfoliating layers and enhances the action of mometasone by promoting its absorption.
Thus, the combination of mometasone and salicylic acid in Moleskin C can both enhance the anti-inflammatory and anti-pruritic action and quickly return the skins’ healthy aesthetic look which is so important for patients with chronic dermatological diseases.
It should be noted that Moleskin C was investigated in clinical trials at the Ivano-Frankivsk National Medical University which proved its full therapeutic equivalence with the original drug product, containing mometasone furoate and salicylic acid.”
Volodymyr Kostiuk, Executive Director of “Farmak”, has ranked the best top managers in his field of work. Volodymyr Kostiuk has been employed by “Farmak” since 2008 and appointed as the Executive Director in 2012. The strategic task of Volodymyr Kostiuk is to strengthen the positions of JSC “Farmak” in the international markets, expand the geography [&helli...
When buying Corvalol, consumers mean a drug under the brand of Farmak, which has been produced at the plant since 1959. This conclusion was made by International Marketing Group during its study of the level of consumer awareness of the drug marked “CORVALOL”. Most of the respondents surveyed noted that the drug called “Corvalol” is […]
As part of the celebration of the 60th anniversary of the first release of Corvalol manufactured by Farmak, leader of the Ukrainian pharmaceutical market, the Ukrainian Book of Records has recognized Corvalol by Farmak as the most known sedative in Ukraine. Corvalol by Farmak is a globally known medicinal product that has already become a […]